Biocartis Group NV: Disclosure of outstanding voting securities

 

Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that 21,667 new shares were issued as a result of the exercise of stock options (each stock option having the form of a warrant) under the 2013 Plan for employees, consultants and management members.

In view hereof, and in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous provisions (the 'Belgian Act'), the outstanding share capital and outstanding voting securities of the Company can be summarised as follows:

  • Total outstanding share capital: EUR 446,697.72;
  • Total outstanding voting securities: 44,669,772 shares;
  • Total outstanding voting rights: 44,669,772 voting rights;
  • Shares that can still be issued: 7,122,089 shares (each share entailing one voting right), of which:
    • 810,804 shares can be issued upon the exercise of 810,804 outstanding stock options (each stock option having the form of a warrant) that are still outstanding under the 2013 Plan for employees, consultants and management members, entitling the holders thereof to acquire one new share per option;
    • 262,934 shares can be issued upon the exercise of 262,934 outstanding stock options (each stock option having the form of a warrant) that are still outstanding under the 2015 Plan for employees, consultants, management members and directors, entitling the holders thereof to acquire one new share per option;
    • 1,340,000 shares can be issued upon the exercise of 1,340,000 outstanding stock options (each stock option having the form of a warrant) that are still outstanding under the 2017 Plan for the CEO, entitling the holder thereof to acquire one new share per option;
    • 4,708,351 shares can be issued pursuant to a conversion option agreement entered into between Koninklijke Philips N.V. ('Philips') and the Company[1].

Pursuant to the Belgian Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

Note

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis offers ten oncology tests and two infectious disease tests in Europe. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.

 

 

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?